Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + pomalidomide + bortezomib + dexamethasone in newly diagnosed multiple myeloma with renal insufficiency
ChiCTR2200064695Phase 2Not yet recruiting
- Sponsor
- Beijing Chaoyang Hospital, Capital Medical University
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor, pomalidomide, bortezomib and dexamethasone in multiple myeloma (MM) and Renal Insufficiency (RI), sponsored by Beijing Chaoyang Hospital, Capital Medical University. Primary endpoint: 3-month overall renal remission rate. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
selinexorpomalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)Renal Insufficiency (RI)
Beyond the preview
Go deeper on ChiCTR2200064695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064695.